Equities

Fusion Antibodies PLC

FAB:LSE

Fusion Antibodies PLC

Health CareHealth Care Providers
  • Price (GBX)16.00
  • Today's Change0.75 / 4.92%
  • Shares traded629.92k
  • 1 Year change107.79%
  • Beta2.1450
Data delayed at least 20 minutes, as of Feb 06 2026 16:18 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Fusion Antibodies plc is a United Kingdom-based collaborative research organization (CRO) company. The Company offers an integrated end-to-end range of antibody discovery, engineering and expression services for all stages of human therapeutic, veterinary therapeutic and diagnostic antibody development. It offers a range of services including antibody discovery/generation, development, characterization, optimization, and small-scale production. In addition, the Company also offers antigen design, antigen expression, antibody purification and sequencing, antibody humanization using Fusion's proprietary CDRx platform and cell line development, producing antibody generating stable cell lines optimized for downstream use by the customer to produce material for clinical trials. Its Integrated Therapeutic Antibody Services (ITA) offering enhances the efficiency of this process by providing a continuous service offering from as early as target nomination to as far as a stable cell line.

  • Revenue in GBP (TTM)1.60m
  • Net income in GBP-1.47m
  • Incorporated2000
  • Employees24.00
  • Location
    Fusion Antibodies PLCSpringbank Industrial Estate1 Springbank RoadBELFAST BT17 0QLUnited KingdomGBR
  • Phone+44 28 9043 2800Fax+44 28 9002 0446
  • Websitehttps://fusionantibodies.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
TheraCryf PLC0.00-2.01m4.51m9.004.51m9.00
Ovoca Bio PLC0.0065.12k5.28m1.005.28m1.00
Cizzle Biotechnology Holdings PLC0.00-1.12m6.14m67.006.14m67.00
Futura Medical PLC7.93m-6.29m7.41m12.007.41m12.00
OptiBiotix Health PLC1.15m-191.00k7.90m5.007.90m5.00
IXICO PLC6.53m-1.65m9.50m79.009.50m79.00
Genflow Biosciences PLC0.00-1.80m10.36m5.0010.36m5.00
Solvonis Therapeutics PLC0.00-2.60m17.02m--17.02m--
Fusion Antibodies PLC1.60m-1.47m20.00m24.0020.00m24.00
Sareum Holdings Plc0.00-4.44m23.47m5.0023.47m5.00
Arecor Therapeutics PLC5.06m-8.10m29.26m37.0029.26m37.00
Poolbeg Pharma PLC0.00-5.71m32.07m10.0032.07m10.00
ImmuPharma PLC0.00-3.93m32.07m6.0032.07m6.00
Data as of Feb 06 2026. Currency figures normalised to Fusion Antibodies PLC's reporting currency: UK Pound GBX

Institutional shareholders

13.82%Per cent of shares held by top holders
HolderShares% Held
Canaccord Genuity Wealth Ltd.as of 30 Sep 20257.83m6.89%
Unicorn Asset Management Ltd.as of 09 Apr 20256.40m5.63%
Octopus Investments Ltd.as of 31 Aug 20251.46m1.29%
Oberon Investments Ltd. (GB Investment Management)as of 30 Jun 20258.31k0.01%
More ▼
Data from 31 Oct 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.